促销!

Dulaglutide

价格范围:$110.00 至 $190.00

+ Free Shipping
SKU: N/A 分类:

Dulaglutide (Trulicity®)

⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy.

Dulaglutide is a recombinant GLP‑1R agonist fusion glycoprotein, produced in CHO cells. It is not a simple short synthetic peptide.

Basic Information

  • CAS No.: 923950-08-7Therapeuti…
  • Structure: Homodimer linked by disulfide bonds. Each monomer = modified GLP‑1 analog + peptide linker + modified human IgG4 Fc fragment
  • Molecular Formula: \(\boldsymbol{C_{2646}H_{4044}N_{704}O_{836}S_{18}}\)National I…
  • Molecular Weight: 62,561 Da (main glycosylated form)Therapeuti…
  • Appearance: White to off-white lyophilized powder
  • Solubility: Soluble in aqueous buffer
  • Storage: Lyophilized powder at -20℃, protect from light and moisture; avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.

Development Background

Dulaglutide is developed by Eli Lilly, brand name Trulicity®, approved for clinical use for type 2 diabetes. It is a long-acting GLP‑1 fusion protein. Native GLP‑1 is rapidly degraded by DPP‑4 with half-life ~2 min. Dulaglutide uses amino acid mutation for DPP‑4 resistance and fuses GLP‑1 analog to IgG4-Fc domain. Larger molecular size reduces renal clearance, prolonging half-life to ~4.7 days, supporting once-weekly dosing. The IgG4-Fc is mutated to eliminate Fcγ receptor binding and minimize immunogenicity.PMC

Mechanism of Action (Research Findings)

  • Activates GLP‑1 receptor (Class B GPCR), elevates intracellular cAMP.
  • Glucose-dependent insulin secretion: Stimulates pancreatic β-cells to release insulin only under high glucose.
  • Suppresses inappropriate glucagon secretion from α-cells, lowering hepatic glucose output.
  • Delays gastric emptying, reduces postprandial blood glucose spikes.
  • Reduces appetite via central GLP‑1 receptor activation in hypothalamus.
  • Cardioprotective effects observed in T2DM models, lowering major adverse cardiovascular events.
  • Resistant to DPP‑4 enzymatic degradation.

Research Areas

  • GLP‑1 receptor pharmacology & GPCR signaling
  • Type 2 diabetes glycemic control models
  • Obesity, appetite regulation & energy metabolism
  • Cardiovascular protection in diabetic animal models
  • Pancreatic beta-cell survival and preservation
  • Comparative pharmacokinetics of long-acting GLP‑1 fusion proteins
Specifications

5mg, 10mg

评价

目前还没有评价

成为第一个“Dulaglutide” 的评价者

您的邮箱地址不会被公开。 必填项已用 * 标注